Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience.

Ritzwoller DP, Carroll NM, Delate T, Hornbrook MC, Kushi L, Bowles EJ, Loggers ET, Menter A.

J Thorac Oncol. 2014 May;9(5):692-701. doi: 10.1097/JTO.0000000000000127.

2.

Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.

Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, Schrag D.

JAMA. 2012 Apr 18;307(15):1593-601. doi: 10.1001/jama.2012.454.

3.

Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.

Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S.

Lung Cancer. 2014 Dec;86(3):350-7. doi: 10.1016/j.lungcan.2014.09.017. Epub 2014 Sep 30.

PMID:
25439437
5.

Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.

Zhu J, Sharma DB, Chen AB, Johnson BE, Weeks JC, Schrag D.

Cancer. 2013 Jun 1;119(11):2048-60. doi: 10.1002/cncr.28022. Epub 2013 Apr 5.

6.

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.

Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY.

J Clin Oncol. 2015 Jul 1;33(19):2197-204. doi: 10.1200/JCO.2014.59.4424. Epub 2015 May 26.

7.

Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.

Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, Brahmer JR, Johnson DH, Sandler A.

J Thorac Oncol. 2012 Nov;7(11):1707-12. doi: 10.1097/JTO.0b013e318265b500.

8.

Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.

Reynolds C, Barrera D, Jotte R, Spira AI, Weissman C, Boehm KA, Pritchard S, Asmar L.

J Thorac Oncol. 2009 Dec;4(12):1537-43. doi: 10.1097/JTO.0b013e3181c0a2f4.

9.

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH.

Ann Oncol. 2014 Jan;25(1):132-8. doi: 10.1093/annonc/mdt489.

10.

Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.

Bonomi PD, Mace J, Mandanas RA, Min M, Olsen M, Youssoufian H, Katz TL, Sheth G, Lee HJ.

J Thorac Oncol. 2013 Mar;8(3):338-45. doi: 10.1097/JTO.0b013e318282ded5.

11.
12.

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.

Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ.

J Thorac Oncol. 2015 Jan;10(1):134-42. doi: 10.1097/JTO.0000000000000366.

13.

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.

Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M; JO19907 Study Group.

Lung Cancer. 2012 Jun;76(3):362-7. doi: 10.1016/j.lungcan.2011.12.005. Epub 2012 Jan 14.

14.

The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.

Shimizu R, Fujimoto D, Kato R, Otoshi T, Kawamura T, Tamai K, Matsumoto T, Nagata K, Otsuka K, Nakagawa A, Otsuka K, Katakami N, Tomii K.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1159-66. doi: 10.1007/s00280-014-2590-x. Epub 2014 Sep 23.

PMID:
25245821
15.

Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.

Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR Jr, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR.

J Thorac Oncol. 2013 Dec;8(12):1519-28. doi: 10.1097/JTO.0000000000000009.

16.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH.

N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.

17.

Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience.

Jardim DL, Gagliato Dde M, Ribeiro KB, Shimada AK, Katz A.

Drugs R D. 2012 Dec 1;12(4):207-16. doi: 10.2165/11636760-000000000-00000.

18.

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.

Nuijten MJ, Aultman R, Carpeño Jde C, Vergnenègre A, Chouaid C, Walzer S, Siebert U.

Curr Med Res Opin. 2011 Nov;27(11):2193-201. doi: 10.1185/03007995.2011.626019. Epub 2011 Oct 4.

PMID:
21970659
19.

NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.

Dy GK, Molina JR, Qi Y, Ansari R, Thomas S, Ross HJ, Soori G, Anderson D, Aubry MC, Meyers J, Adjei AA, Mandrekar S, Adjei AA.

J Thorac Oncol. 2014 Aug;9(8):1146-53. doi: 10.1097/JTO.0000000000000217.

20.

Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.

Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK.

Clin Lung Cancer. 2015 May;16(3):200-8. doi: 10.1016/j.cllc.2014.11.004. Epub 2014 Nov 18.

PMID:
25516338
Items per page

Supplemental Content

Write to the Help Desk